Publications by authors named "Neil H Bander"

71Publications

Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.

Urol Oncol 2020 Nov 27;38(11):848.e9-848.e16. Epub 2020 Jun 27.

Department of Urology, Weill Cornell Medicine, New York, NY; Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, NewYork Presbyterian Hospital, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.05.028DOI Listing
November 2020

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.

Mol Cancer Ther 2018 09 11;17(9):1927-1940. Epub 2018 Jun 11.

Department of Urology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1138DOI Listing
September 2018

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.

Mol Cancer Res 2016 11 25;14(11):1045-1053. Epub 2016 Jul 25.

Department of Urology, Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-16-0193DOI Listing
November 2016

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Urol Oncol 2016 12 17;34(12):530.e15-530.e21. Epub 2016 Oct 17.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.07.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464417PMC
December 2016

Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.

Appl Immunohistochem Mol Morphol 2017 04;25(4):271-276

*Department of Radiation Oncology, Stich Radiation Center †Laboratory of Urologic Oncology, Department of Urology ‡Department of Pathology, Division of Gynecologic and Perinatal Pathology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000297DOI Listing
April 2017

Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.

J Clin Endocrinol Metab 2016 Mar 15;101(3):981-7. Epub 2016 Jan 15.

Departments of Surgery (M.J.P.C., D.A.K., T.B., A.A., R.Z., T.J.F.), Pathology and Laboratory Medicine (T.S., Y.-F.L.), Urology (H.L., S.T.T., N.H.B.), Nuclear Medicine (Y.S.J.), and Medicine (A.M., S.T.T.); New York Presbyterian Hospital-Weill Cornell Medical College and Department of Physiology and Biophysics (M.J.P.C., O.E.), Weill Cornell Medical College-Institute for Computational Biomedicine, New York, New York 10065; and HRH Prince Alwaleed Bin Talal Bin Abdulaziz Al-Saud Institute for Computational Biomedicine (O.E.), Weill Cornell Medical College, New York, New York 10021.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2015-4021DOI Listing
March 2016

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

EJNMMI Res 2015 29;5:28. Epub 2015 Apr 29.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA ; Department of Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-015-0104-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425739PMC
May 2015

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.

Onco Targets Ther 2014 3;7:2227-36. Epub 2014 Dec 3.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY, USA ; Department of Urology, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.dovepress.com/microtubule-inhibitor-based-antibod
Publisher Site
http://dx.doi.org/10.2147/OTT.S46887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259504PMC
December 2014

The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.

Nat Commun 2014 Nov 21;5:5383. Epub 2014 Nov 21.

1] Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, 413 East 69th Street, Room 1402, New York, New York 10021, USA [2] Institute for Precision Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241506PMC
November 2014

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

PLoS One 2013 27;8(12):e85143. Epub 2013 Dec 27.

Deparment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, New York, United States of America ; Department of Urology, Weill Cornell Medical College, New York, New York, United States of America ; Weill Cornell Cancer Center, Weill Cornell Medical College, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085143PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874033PMC
February 2015

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

APMIS 2014 Jun 5;122(6):482-9. Epub 2013 Dec 5.

Department of Radiation Oncology, Stich Radiation Center, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apm.12195DOI Listing
June 2014

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Front Oncol 2013 26;3:214. Epub 2013 Aug 26.

Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College , New York, NY , USA ; Department of Urology, Weill Cornell Medical College , New York, NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752585PMC
August 2013

Antibody-drug conjugate target selection: critical factors.

Authors:
Neil H Bander

Methods Mol Biol 2013 ;1045:29-40

Weill-Cornell Medical College, Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-541-5_2DOI Listing
February 2014

Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system.

Biomed Microdevices 2013 Dec;15(6):941-8

Department of Biomedical Engineering, Cornell University, Ithaca, NY, 14853, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10544-013-9784-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830616PMC
December 2013

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Clin Cancer Res 2013 Sep 28;19(18):5182-91. Epub 2013 May 28.

Authors' Affiliations: Weill Cornell Medical College (WCMC); Weill Cornell Cancer Center; Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York; and University of North Carolina Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778101PMC
September 2013

Antibody-drug conjugate technology development for hematologic disorders.

Clin Adv Hematol Oncol 2012 Aug;10(8 Suppl 10):1-16

Weill Medical College/Cornell University, New York-Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
August 2012

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

Nanomedicine (Lond) 2013 May 17;8(5):687-98. Epub 2012 Oct 17.

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nnm.12.134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694785PMC
May 2013

Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Biomed Microdevices 2012 Apr;14(2):401-7

Sibley School of Mechanical and Aerospace Engineering, Cornell University, 245 Upson Hall, Ithaca, NY 14853, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10544-011-9616-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074911PMC
April 2012

Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Arch Pathol Lab Med 2011 Nov;135(11):1486-9

Department of Radiation Oncology, Weill Cornell Medical College of Cornell University, Stich Radiation Center, 525 E 68th St, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2010-0740-OADOI Listing
November 2011

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

J Nucl Med 2011 Oct 9;52(10):1608-15. Epub 2011 Sep 9.

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.111.092098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537833PMC
October 2011

Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Bioconjug Chem 2011 Aug 27;22(8):1700-5. Epub 2011 Jul 27.

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda Maryland 20892, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc2002715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157565PMC
August 2011

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Proc Natl Acad Sci U S A 2011 Jun 23;108(23):9578-82. Epub 2011 May 23.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1106383108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111331PMC
June 2011

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

J Nucl Med 2010 Aug 21;51(8):1293-300. Epub 2010 Jul 21.

Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.110.076174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998794PMC
August 2010

Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.

Prostate 2010 Sep;70(12):1286-94

Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.21164
Publisher Site
http://dx.doi.org/10.1002/pros.21164DOI Listing
September 2010

ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.

Nanomedicine (Lond) 2010 Apr;5(3):361-8

Laboratory of Nanomedicine & Biomaterials, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/nnm.10.6
Publisher Site
http://dx.doi.org/10.2217/nnm.10.6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901911PMC
April 2010

Editorial comment.

Authors:
Neil H Bander

J Urol 2009 Sep 17;182(3):947-8. Epub 2009 Jul 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.05.131DOI Listing
September 2009

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.

Prostate 2009 Oct;69(14):1579-85

Laboratory of Urological Oncology, Department of Urology, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pros.21004
Publisher Site
http://dx.doi.org/10.1002/pros.21004DOI Listing
October 2009

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

ChemMedChem 2008 Sep;3(9):1311-5

Laboratory of Nanomedicine and Biomaterials, Department of Anesthesia, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.200800091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131111PMC
September 2008

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.

Int J Oncol 2007 Nov;31(5):1199-203

Urologic Oncology Research Laboratory, Department of Urology, Weill Medical College of Cornell University-New York Presbyterian Hospital, New York, NY, USA.

View Article

Download full-text PDF

Source
November 2007

Active and passive immunotherapy: vaccines and antibodies.

BJU Int 2007 May;99(5 Pt B):1301-4

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2007.06835.xDOI Listing
May 2007

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

J Clin Oncol 2007 Feb;25(5):540-7

Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.07.8097DOI Listing
February 2007

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

Clin Genitourin Cancer 2006 Mar;4(4):249-56

Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731170147
Publisher Site
http://dx.doi.org/10.3816/CGC.2006.n.003DOI Listing
March 2006

Technology insight: monoclonal antibody imaging of prostate cancer.

Authors:
Neil H Bander

Nat Clin Pract Urol 2006 Apr;3(4):216-25

New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpuro0452DOI Listing
April 2006

Antibody-based therapeutics: focus on prostate cancer.

Cancer Metastasis Rev 2005 Dec;24(4):521-37

Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10555-005-6194-0
Publisher Site
http://dx.doi.org/10.1007/s10555-005-6194-0DOI Listing
December 2005

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Clin Cancer Res 2005 Oct;11(19 Pt 2):7195s-7200s

Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-1004-0023DOI Listing
October 2005

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

J Nucl Med 2005 May;46(5):850-8

Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, 525 E. 68th Street, STARR-221, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
May 2005

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

J Clin Oncol 2005 Jul 18;23(21):4591-601. Epub 2005 Apr 18.

Department of Urology, Weill Medical College of Cornell University, 525 E 68th St, E-300, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.160DOI Listing
July 2005

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

J Nucl Med 2005 Apr;46(4):634-41

Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
April 2005

Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy.

Bioconjug Chem 2004 Nov-Dec;15(6):1174-81

Center for Biologic Nanotechnology, Department of Internal Medicine, Division of Allergy, University of Michigan, 9220 MSRB III, Box 0648, Ann Arbor, Michigan 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bc0499127DOI Listing
April 2005

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

J Clin Oncol 2004 Jul 1;22(13):2522-31. Epub 2004 Jun 1.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.09.154DOI Listing
July 2004

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.

Prostate 2004 Feb;58(2):145-55

Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.10281DOI Listing
February 2004

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Semin Oncol 2003 Oct;30(5):667-76

Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0093-7754(03)00358-0DOI Listing
October 2003

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

J Urol 2003 Nov;170(5):1717-21

Department of Urology, Division of Nuclear Medicine, New York-Presbyterian Hospital/Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000091655.77601.0cDOI Listing
November 2003

A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.

Mol Biol Cell 2003 Dec 3;14(12):4835-45. Epub 2003 Oct 3.

Department of Pathology and Laboratory Medicine, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1091/mbc.e02-11-0731DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284788PMC
December 2003

Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity.

Cancer Res 2003 May;63(10):2645-8

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
May 2003

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

J Nucl Med 2003 Apr;44(4):610-7

Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/content/44/4/610.full.pdf
Web Search
April 2003

Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line.

Prostate 2003 Apr;55(1):9-19

Department of Pathology and Laboratory Medicine, Room 13-344 CHS, University of California Los Angeles, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.10203DOI Listing
April 2003